Skip to content

A prospective cohort study and nested case-control study of intranasal insulin for postoperative delirium in elderly patients with hip fracture

A prospective cohort study and nested case-control study of intranasal insulin for postoperative delirium in elderly patients with hip fracture

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084380
Enrollment
Unknown
Registered
2024-05-15
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative delirium

Interventions

Insulin nasal administration queue:None
Routine treatment queue for hip fractures:None
POD group/Non POD group:None

Sponsors

Yichang Central People's Hospita
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Age = 65 years old, regardless of gender; 2. ASA classification: Level I-III; 3. BMI = 28kg/?; 4. Preoperative diagnosis of hip fracture, femoral trochanter fracture, intertrochanteric fracture, or femoral neck fracture; 5. Have the ability to act independently, have clear awareness, and be able to cooperate in completing experiments.

Exclusion criteria

Exclusion criteria: 1. Patients who are contraindicated for intranasal administration (such as those with damaged or diseased nasal mucosa); 2. Patients with a history of insulin allergy; 3. Have a history of cerebrovascular accidents with sequelae; 4. Patients with neurological disorders such as Alzheimer's or Parkinson's disease; 5. Patients with severe liver and kidney diseases; 6. Patients with diseases that can cause an increase in inflammatory factors (including but not limited to autoimmune diseases); 7. Patients who refuse the experimental protocol or are lost to follow-up.

Design outcomes

Primary

MeasureTime frame
CAM-ICU Assessment Scale;

Secondary

MeasureTime frame
MMSE;Blood inflammatory factors;Inflammatory factors in cerebrospinal fluid;

Countries

China

Contacts

Public ContactAihua Shu

Yichang Central People's Hospital

yymz2022@yeah.net+86 139 7202 1520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026